Search This Blog

Monday, March 9, 2026

Xenon Phase 3 X-TOLE2 azetukalner in focal onset seizures meets primary, key secondary endpoint

 

Xenon Pharma’s Phase 3 X-TOLE2 azetukalner trial in focal onset seizures meets primary and key secondary endpoints

  • X-TOLE2 results showed strong efficacy and favorable safety profile for azetukalner in focal onset seizures.
  • Xenon plans to submit a U.S. FDA NDA for azetukalner in the third quarter of 2026.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)